DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024" report to their offering.
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an important cause of hospitalizations and deaths in elderly adults.
Today, Medimmune's Synagis (palivizumab) is the only licensed intervention for the prevention of RSV in infants at a high risk of severe infection. This humanized, mouse monoclonal antibody (mAb) was first approval in 1998, and while it is an efficacious prophylactic intervention, its short 20-day half-life necessitates monthly dosing during the RSV season. Moreover, the high cost of Synagis limits its use to certain subgroups of infants who are at high risk of severe RSV infection, and it is not indicated for use in elderly adults, leaving a key population of high-risk individuals unprotected.
Furthermore, due to the absence of effective RSV-specific antivirals, the treatment of RSV infections is largely restricted to a number of supportive treatment options. GlobalData projects the global RSV marketplace - which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) - to experience unprecedented growth from 2014-2024, driven by the arrival of novel approaches to prevention and management of RSV.
- The global RSV marketplace - which, for the purposes of this report, encompasses the sales of products for the prevention or treatment of RSV in the 7MM - was worth approximately $640m in 2014. GlobalData projects the market to surpass $2.3bn in sales by 2024, at a compound annual growth rate (CAGR) of 29.9% from 2014-2024. The sales are projected to originate predominantly from the US (a 62% market share), followed distantly by the 5EU (a 29% market share).
- The anticipated arrival of novel prophylactic mAbs that boast improved dosing criteria compared with Synagis, led by MedImmune's MEDI8897, will be a principal driver of RSV market growth across the 7MM. The licensure of the first adult vaccine to offer protection against RSV, Novavax's RSV-F Vaccine, will also stimulate rapid growth in a previously untapped segment of the marketplace.
- A persistent lack of patient and physician awareness of RSV in adult patients - specifically the infection's substantial impact on morbidity and mortality in the elderly - will serve as a key impediment to market growth from 2014-2024.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Symptoms and Prognosis
3.3 Quality of Life
3.4 Disease Management
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for RSV Infection (2014-2024)
5 Current Treatment Options
5.2 Product Profiles - RSV Prophylactics
5.3 Product Profiles - RSV Therapeutics
5.4 Other Supportive Measures
6 Unmet Needs and Opportunities
6.2 Effective Therapeutic Interventions
6.3 Prophylactic Vaccines
6.4 A Prophylactic mAb with an Increased Half-Life
6.5 Point-of-care Testing for RSV in Adult Patients
6.6 Increased Awareness of RSV Infections in Adults
7 Research and Development Strategies
7.2 Development of Novel Prophylactic Antibodies with Increased Cost-Effectiveness
7.3 Technological Approaches to Vaccine Development
7.4 Leveraging the FDA's Fast Track Program
7.5 Development of RSV Therapeutics
7.6 Clinical Trial Design
8 Pipeline Assessment
8.2 Promising Drugs in Clinical Development - Prophylactic Agents
8.3 Promising Drugs in Clinical Development - Therapeutic Agents
8.4 Innovative Early-Stage Approaches
9 Pipeline Valuation
9.2 Clinical Benchmark of Key Pipeline Products
9.3 Commcercial Benchmark of Key Pipeline Products
9.4 Competitive Assessment
9.5 Top-Line 10-Year Forecast
- Janssen (Johnson & Johnson)
- Gilead Sciences
- Ark Biosciences
- Biota Pharmaceuticals
- Romark Laboratories
- Spring Bank Pharmaceuticals
- Immunovaccine, Inc.
- Bavarian Nordic
- Meda Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/hm7lq5/opportunityanalyze